Cargando…

A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease

BACKGROUND: Pulmonary veno-occlusive disease (PVOD) is a rare, progressive, and oft-fatal condition of pulmonary arterial hypertension that is typically difficult to diagnose and treat. However, with the development of next-generation sequencing technology, an increasing number of patients with PVOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chun, Du, Qiang, Wang, Sha, Zhang, Ruifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710057/
https://www.ncbi.nlm.nih.gov/pubmed/36451176
http://dx.doi.org/10.1186/s12890-022-02256-9
_version_ 1784841289649356800
author Zhang, Chun
Du, Qiang
Wang, Sha
Zhang, Ruifeng
author_facet Zhang, Chun
Du, Qiang
Wang, Sha
Zhang, Ruifeng
author_sort Zhang, Chun
collection PubMed
description BACKGROUND: Pulmonary veno-occlusive disease (PVOD) is a rare, progressive, and oft-fatal condition of pulmonary arterial hypertension that is typically difficult to diagnose and treat. However, with the development of next-generation sequencing technology, an increasing number of patients with PVOD are being diagnosed. METHODS: Initially, we used whole exome sequencing (WES) to identify the proband as a rare compound heterozygous mutation of EIF2AK4 in PVOD. Subsequently, the parents of patient underwent EIF2AK4 screening by Sanger sequencing. RESULTS: In this study, we describe the family tree of a patient with PVOD with a rare compound heterozygous EIF2AK4 mutation. Moreover, we identified a new EIF2AK4 mutation, c.2236_2237insAAGTCCTTCT, in exon 12 of the proband and his mother. This frameshift mutation led to premature termination of the coding protein sequence and widespread loss of protein function, which promoted the development of PVOD. CONCLUSIONS: Our results expand our understanding of the EIF2AK4 mutation spectrum in patients with PVOD, as well as highlight the clinical applicability of WES.
format Online
Article
Text
id pubmed-9710057
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97100572022-12-01 A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease Zhang, Chun Du, Qiang Wang, Sha Zhang, Ruifeng BMC Pulm Med Research Article BACKGROUND: Pulmonary veno-occlusive disease (PVOD) is a rare, progressive, and oft-fatal condition of pulmonary arterial hypertension that is typically difficult to diagnose and treat. However, with the development of next-generation sequencing technology, an increasing number of patients with PVOD are being diagnosed. METHODS: Initially, we used whole exome sequencing (WES) to identify the proband as a rare compound heterozygous mutation of EIF2AK4 in PVOD. Subsequently, the parents of patient underwent EIF2AK4 screening by Sanger sequencing. RESULTS: In this study, we describe the family tree of a patient with PVOD with a rare compound heterozygous EIF2AK4 mutation. Moreover, we identified a new EIF2AK4 mutation, c.2236_2237insAAGTCCTTCT, in exon 12 of the proband and his mother. This frameshift mutation led to premature termination of the coding protein sequence and widespread loss of protein function, which promoted the development of PVOD. CONCLUSIONS: Our results expand our understanding of the EIF2AK4 mutation spectrum in patients with PVOD, as well as highlight the clinical applicability of WES. BioMed Central 2022-11-30 /pmc/articles/PMC9710057/ /pubmed/36451176 http://dx.doi.org/10.1186/s12890-022-02256-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Zhang, Chun
Du, Qiang
Wang, Sha
Zhang, Ruifeng
A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease
title A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease
title_full A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease
title_fullStr A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease
title_full_unstemmed A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease
title_short A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease
title_sort rare compound heterozygous eif2ak4 mutation in pulmonary veno-occlusive disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710057/
https://www.ncbi.nlm.nih.gov/pubmed/36451176
http://dx.doi.org/10.1186/s12890-022-02256-9
work_keys_str_mv AT zhangchun ararecompoundheterozygouseif2ak4mutationinpulmonaryvenoocclusivedisease
AT duqiang ararecompoundheterozygouseif2ak4mutationinpulmonaryvenoocclusivedisease
AT wangsha ararecompoundheterozygouseif2ak4mutationinpulmonaryvenoocclusivedisease
AT zhangruifeng ararecompoundheterozygouseif2ak4mutationinpulmonaryvenoocclusivedisease
AT zhangchun rarecompoundheterozygouseif2ak4mutationinpulmonaryvenoocclusivedisease
AT duqiang rarecompoundheterozygouseif2ak4mutationinpulmonaryvenoocclusivedisease
AT wangsha rarecompoundheterozygouseif2ak4mutationinpulmonaryvenoocclusivedisease
AT zhangruifeng rarecompoundheterozygouseif2ak4mutationinpulmonaryvenoocclusivedisease